Adjusted EBITDA is now expected to grow by 15–19%, compared with 8–14% previously. The upgrade mainly reflects continued strong US sales of the migraine drug Vyepti and stronger-than-expected performance in Lundbeck’s Partner Markets. The higher EBITDA outlook is driven mainly by the higher revenue expectations.

Lundbeck now expects R&D investments of about DKK 5.6–5.7 billion for the year. The company will publish its interim report for January–September 2026 shortly.